J. Jonathan Mazelsky's most recent trade in DENTSPLY Sirona Inc was a trade of 279 Common Stock done . Disclosure was reported to the exchange on July 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 279 | 28,091 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 75 | 9,234 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 1,561 | 9,159 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 13,880 | 27,812 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2025 | 147 | 13,932 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2025 | 74 | 7,597 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 1,687 | 7,522 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 25,932 | 25,932 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 444.53 per share. | 13 Feb 2025 | 1,222 | 83,282 (0%) | 0% | 444.5 | 543,216 | Common Stock |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,100 | 2,198 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,100 | 84,504 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 958 | 83,404 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 958 | 958 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 689 | 82,446 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 689 | 0 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 217 | 217 | - | - | Incentive Stock Option (right-to-buy) | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 115 | 13,784 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 38 | 5,835 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2024 | 1,340 | 5,797 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2024 | 80 | 13,669 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2024 | 22 | 4,456 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 935 | 4,433 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2024 | 384 | 81,902 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2024 | 384 | 0 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 455.08 per share. | 05 Aug 2024 | 170 | 81,732 (0%) | 0% | 455.1 | 77,364 | Common Stock |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2024 | 86 | 13,588 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2024 | 21 | 3,497 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2024 | 994 | 3,476 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 7,994 | 13,502 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2024 | 26 | 5,508 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2024 | 12 | 2,481 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | J. Mazelsky Jonathan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2024 | 761 | 2,469 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Feb 2024 | 550 | 81,496 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Mazelsky Jonathan J. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2024 | 483 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| IDEXX Laboratories | Mazelsky Jonathan J. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 206.94 per share. | 21 Feb 2024 | 483 | 82,046 (0%) | 0% | 206.9 | 99,952 | Common Stock |
| IDEXX Laboratories | Jonathan Mazelsky J. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 21,335 | 21,335 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Jonathan Mazelsky J. | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 560.56 per share. | 14 Feb 2024 | 1,839 | 81,563 (0%) | 0% | 560.6 | 1,030,870 | Common Stock |
| IDEXX Laboratories | Mazelsky Jonathan J. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 1,100 | 83,402 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 1,100 | 3,298 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Jonathan Mazelsky J. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 974 | 80,655 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | J. Jonathan Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 974 | 0 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | J. Jonathan Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 958 | 1,916 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | J. Mazelsky Jonathan | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 958 | 82,302 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Mazelsky Jonathan J. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 689 | 81,344 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 689 | 689 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Jonathan Mazelsky J. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 435 | 79,681 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Mazelsky Jonathan J. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 435 | 0 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 178 | 178 | - | - | Incentive Stock Option (right-to-buy) | |
| IDEXX Laboratories | Mazelsky Jonathan J. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2024 | 12,000 | 29,260 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.85 per share. | 07 Feb 2024 | 12,000 | 91,246 (0%) | 0% | 67.9 | 814,200 | Common Stock |
| IDEXX Laboratories | Mazelsky Jonathan J. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 571.71 per share. | 07 Feb 2024 | 5,356 | 85,890 (0%) | 0% | 571.7 | 3,062,061 | Common Stock |
| IDEXX Laboratories | Jonathan Mazelsky J. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 572.53 per share. | 07 Feb 2024 | 4,124 | 81,766 (0%) | 0% | 572.5 | 2,361,094 | Common Stock |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 574.75 per share. | 07 Feb 2024 | 1,353 | 79,951 (0%) | 0% | 574.8 | 777,639 | Common Stock |
| IDEXX Laboratories | Mazelsky Jonathan J. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 575.48 per share. | 07 Feb 2024 | 705 | 79,246 (0%) | 0% | 575.5 | 405,711 | Common Stock |
| IDEXX Laboratories | J. Mazelsky Jonathan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 573.19 per share. | 07 Feb 2024 | 462 | 81,304 (0%) | 0% | 573.2 | 264,814 | Common Stock |
| DENTSPLY Sirona Inc | J. Mazelsky Jonathan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 21 | 5,481 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | J. Jonathan Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 6 | 1,707 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | Mazelsky J. Jonathan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2023 | 702 | 1,701 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| IDEXX Laboratories | J. Mazelsky Jonathan | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.54 per share. | 04 Dec 2023 | 13,424 | 86,361 (0%) | 0% | 79.5 | 1,067,745 | Common Stock |
| IDEXX Laboratories | J. Jonathan Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2023 | 13,424 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 512.95 per share. | 04 Dec 2023 | 5,804 | 80,557 (0%) | 0% | 513.0 | 2,977,162 | Common Stock |
| IDEXX Laboratories | Mazelsky Jonathan J. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 513.51 per share. | 04 Dec 2023 | 1,324 | 79,233 (0%) | 0% | 513.5 | 679,887 | Common Stock |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2023 | 22 | 5,460 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2023 | 4 | 998 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Sep 2023 | 729 | 993 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 384 | 10,443 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 384 | 73,095 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 504.08 per share. | 05 Aug 2023 | 170 | 72,925 (0%) | 0% | 504.1 | 85,694 | Common Stock |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2023 | 18 | 5,437 (0%) | 0% | 0 | Common Stock | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2023 | 263 | 263 | - | - | Phantom Stock (Directors Deferred Compensation) DDC | |
| DENTSPLY Sirona Inc | Jonathan J. Mazelsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 5,419 | 5,419 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 18 May 2023 | 602 | 72,699 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 178.26 per share. | 04 May 2023 | 560 | 73,301 (0%) | 0% | 178.3 | 99,826 | Common Stock |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 560 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 503.65 per share. | 14 Feb 2023 | 1,657 | 72,726 (0%) | 0% | 503.6 | 834,548 | Common Stock |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 974 | 12,475 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 974 | 72,735 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 959 | 10,827 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 959 | 74,383 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 689 | 11,786 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 689 | 73,424 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 504 | 13,884 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 504 | 71,326 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 435 | 13,449 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 435 | 71,761 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 21,256 | 21,256 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 12,181 | 12,181 | - | - | Premium Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 4,398 | 14,388 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 201 | 201 | - | - | Incentive Stock Option (right-to-buy) | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Nov 2022 | 18,998 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.00 per share. | 14 Nov 2022 | 18,998 | 81,304 (0%) | 0% | 62 | 1,177,876 | Common Stock |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 434.26 per share. | 14 Nov 2022 | 6,385 | 73,947 (0%) | 0% | 434.3 | 2,772,760 | Common Stock |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 435.07 per share. | 14 Nov 2022 | 2,543 | 71,404 (0%) | 0% | 435.1 | 1,106,386 | Common Stock |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 433.37 per share. | 14 Nov 2022 | 972 | 80,332 (0%) | 0% | 433.4 | 421,240 | Common Stock |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 435.88 per share. | 14 Nov 2022 | 600 | 70,804 (0%) | 0% | 435.9 | 261,527 | Common Stock |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.00 per share. | 07 Nov 2022 | 24,002 | 75,536 (0%) | 0% | 52 | 1,248,104 | Common Stock |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2022 | 24,002 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 382.81 per share. | 07 Nov 2022 | 3,704 | 68,432 (0%) | 0% | 382.8 | 1,417,912 | Common Stock |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 384.47 per share. | 07 Nov 2022 | 3,018 | 62,698 (0%) | 0% | 384.5 | 1,160,316 | Common Stock |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 383.29 per share. | 07 Nov 2022 | 2,716 | 65,716 (0%) | 0% | 383.3 | 1,041,006 | Common Stock |
| IDEXX Laboratories | Jonathan J. Mazelsky | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 379.50 per share. | 07 Nov 2022 | 2,000 | 72,636 (0%) | 0% | 379.5 | 758,999 | Common Stock |